ARTICLE | Emerging Company Profile
Company launches with $92 million to develop antibody-drug conjugates spun out of Synaffix
By Lauren Martz, Executive Director, Biopharma Intelligence
October 29, 2024 12:20 AM UTC
With backing from Novo Ventures, a pharma veteran as COO, and a pair of preclinical antibody-drug conjugates, Kivu Bioscience is putting the non-core asset spinout model to the test. It’s also on a mission to elevate tolerability as a priority for the next-generation of ADCs.
The biotech was launched with a license to two antibody-drug conjugates that were constructed using the GlycoConnect site-specific conjugation technology of Synaffix B.V., then spun out last year when Synaffix was acquired by Lonza Group Ltd. (SIX:LONN)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653984/kivu-advancing-safer-adcs-against-established-targets